Tysabri continues to prop up Elan with 18% revenue jump
This article was originally published in Scrip
Executive Summary
Irish pharma company Elan reported a 5% increase in total revenue to $1.17 billion for 2010 driven by increased revenue from Tysabri (natalizumab). Elan's portion of sales from the multiple sclerosis (MS) treatment, which is co-marketed with Biogen Idec, increased by 18% to $851.5 million for the full year.